Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2012 - 2018)
Catalyst Pharmaceuticals posted quarterly Current Deferred Revenue of $33408.0 for Q4 2018, up 39.14% year-on-year from $24011.0 in Q4 2017, and up 52.45% on a QoQ basis from $21914.0 in Q3 2018.
Catalyst Pharmaceuticals (CPRX) has 7 years of Current Deferred Revenue data on file, last reported at $33408.0 in Q4 2018.
- For the quarter ending Q4 2018, Current Deferred Revenue rose 39.14% year-over-year to $33408.0; the trailing twelve-month figure through Dec 2018 stood at $33408.0 (up 39.14% YoY), and the FY2018 full-year result was $33408.0, up 39.14% from the prior year.
- Current Deferred Revenue for Q4 2018 stood at $33408.0, up from $21914.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $33408.0 in Q4 2018 and bottomed at $3254.0 in Q1 2014.
- The 5-year median for Current Deferred Revenue is $18094.0 (2016), against an average of $16181.7.
- The widest annual swing landed in 2015, when Current Deferred Revenue soared 335.14%; it then decreased 2.27% in 2018.
- A 5-year view of Current Deferred Revenue shows it stood at $4158.0 in 2014, then jumped by 335.14% to $18093.0 in 2015, then increased by 0.01% to $18094.0 in 2016, then soared by 32.7% to $24011.0 in 2017, then surged by 39.14% to $33408.0 in 2018.
- The last three Current Deferred Revenue figures came in at $33408.0 (Q4 2018), $21914.0 (Q3 2018), and $27184.0 (Q2 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 33,408.00 |
| Sep 30, 2018 | 21,914.00 |
| Jun 30, 2018 | 27,184.00 |
| Mar 31, 2018 | 25,597.00 |
| Dec 31, 2017 | 24,011.00 |
| Sep 30, 2017 | 22,424.00 |
| Jun 30, 2017 | 20,867.00 |
| Mar 31, 2017 | 19,328.00 |
| Dec 31, 2016 | 18,094.00 |
| Dec 31, 2015 | 18,093.00 |
| Sep 30, 2015 | 18,093.00 |
| Jun 30, 2015 | 5,702.00 |
| Mar 31, 2015 | 4,930.00 |
| Dec 31, 2014 | 4,158.00 |
| Sep 30, 2014 | 4,270.00 |
| Jun 30, 2014 | 3,762.00 |
| Mar 31, 2014 | 3,254.00 |
| Dec 31, 2013 | 2,746.00 |
| Sep 30, 2013 | 2,245.00 |
| Jun 30, 2013 | 1,752.00 |
| Mar 31, 2013 | 1,259.00 |
| Dec 31, 2012 | 765.00 |